可切除非小细胞肺癌新辅助免疫治疗研究进展  

Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

作　　者：齐畅 田攀文[1,4] 李为民[1,2,3] Chang QI;Panwen TIAN;Weimin LI(Department of Pulmonary and Critical Care Medicine,State Key Laboratory of Respiratory Health and Multimorbidity,Precision Medicine Key Laboratory of Sichuan Province,West China Hospital,Sichuan University;Institute of Respiratory Health,Frontiers Science Center for Disease-related Molecular Network,West China Hospital,Sichuan University;The Research Units of West China,Chinese Academy of Medical Sciences,West China Hospital;Lung Cancer Center/Lung Cancer Institute,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院呼吸与危重症医学科,呼吸和共病全国重点实验室,精准医学四川省重点实验室,成都610041 [2]四川大学华西医院呼吸健康研究所,疾病分子网络前沿科学中心,呼吸和共病研究院 [3]四川大学华西医院中国医学科学院创新单元 [4]四川大学华西医院肺癌中心

出　　处：《中国肺癌杂志》2024年第2期138-146,共9页Chinese Journal of Lung Cancer

基　　金：国家自然科学基金项目(No.82072598,No.92159302);四川省科技厅重大专项(No.2022ZDZX0018);四川大学华西医院1-3-5卓越计划项目(No.ZYJC21052,No.ZYGD22009)资助。

摘　　要：近年来,免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)对晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者预后的改善已成为共识,越来越多的临床研究也逐渐证明了免疫治疗对于可切除NSCLC患者的重要价值。然而,目前关于新辅助治疗背景下免疫联合策略的探索、治疗相关副作用、预后生物标志物等问题仍存在争议。本文综述了可切除NSCLC患者新辅助免疫治疗的最新进展,引发了新的思考,并讨论了其在临床应用中的优势及挑战。In recent years,there has been a consensus regarding the enhancement of prognosis in patients with advanced non-small cell lung cancer(NSCLC)through the utilization of immune checkpoint inhibitors(ICIs).Numerous clinical studies have also demonstrated the substantial value of immunotherapy for resectable NSCLC patients.Nevertheless,there remain controversies surrounding the exploration of immune combination strategies,treatment-related side effects,prognostic biomarkers,as well as other issues in the neoadjuvant therapy setting.Consequently,this article presents a comprehensive overview of the recent advancements in neoadjuvant immunotherapy for resectable NSCLC,stimulating fresh perspectives and delving into its merits and challenges in clinical application.

关 键 词：肺肿瘤 新辅助治疗 免疫检查点抑制剂 围手术期 可切除非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]